Cargando…

Migraine and tension-type headache treated with stromal vascular fraction: a case series

INTRODUCTION: Chronic migraines and tension-type headaches are debilitating diseases affecting 1.4 to 2.2% of the population with both quality of life and economic implications. To date, the pain associated with migraine and tension-type headaches has been controlled with a range of medications, wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bright, Ralph, Bright, Matthew, Bright, Pelin, Hayne, Shannon, Thomas, Wayne D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088303/
https://www.ncbi.nlm.nih.gov/pubmed/24981130
http://dx.doi.org/10.1186/1752-1947-8-237
_version_ 1782324926158471168
author Bright, Ralph
Bright, Matthew
Bright, Pelin
Hayne, Shannon
Thomas, Wayne D
author_facet Bright, Ralph
Bright, Matthew
Bright, Pelin
Hayne, Shannon
Thomas, Wayne D
author_sort Bright, Ralph
collection PubMed
description INTRODUCTION: Chronic migraines and tension-type headaches are debilitating diseases affecting 1.4 to 2.2% of the population with both quality of life and economic implications. To date, the pain associated with migraine and tension-type headaches has been controlled with a range of medications, with varying levels of success. In addition, the side-effect profile of these medications, as well as their potential for addiction, has been a cause for concern for both patients and physicians. CASE PRESENTATIONS: Four women with long histories of migraine or frequent tension-type headache that meet the International Classification of Headache Disorders criteria for Chronic Migraine or Tension-type Headaches were given a systemic treatment(s) of autologous stromal vascular fraction or autologous ‘StroMed’ isolated from lipoaspirate. StroMed is stromal vascular fraction cells prepared by ultrasonic cavitation. Two of the four patients, both of whom are Arab women aged 40 and 36 years, ceased having migraines after 1 month, for a period of 12 to 18 months. The third patient, a Slavic woman aged 43 years, had a significant decrease in the frequency and severity of migraines with only seven migraines over 18 months. The fourth patient, an Asian woman aged 44 years, obtained a temporary decrease for a period of a month and was retreated 18 months later and has been free of migraines to date for 1 month. Pain medication was typically reduced from prescribed opioid analgesia to non-steroidal anti-inflammatory drugs and paracetamol. CONCLUSIONS: This case series is the first to provide evidence of the efficacy of autologous StroMed and stromal vascular fraction in the treatment of migraine and tension-type headache. The treatment of this disease by stromal vascular fraction adds a new dimension to its clinical applicability and suggests a relatively simple treatment that may help address the symptoms of the disease. Given what is known about the components of the stromal vascular fraction and how they act, the information presented in this case series may also further our knowledge of the etiology and pathophysiology of migraine and tension-type headaches. This treatment is simple, looks to be extremely effective and has been life changing for these patients.
format Online
Article
Text
id pubmed-4088303
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40883032014-07-10 Migraine and tension-type headache treated with stromal vascular fraction: a case series Bright, Ralph Bright, Matthew Bright, Pelin Hayne, Shannon Thomas, Wayne D J Med Case Rep Case Report INTRODUCTION: Chronic migraines and tension-type headaches are debilitating diseases affecting 1.4 to 2.2% of the population with both quality of life and economic implications. To date, the pain associated with migraine and tension-type headaches has been controlled with a range of medications, with varying levels of success. In addition, the side-effect profile of these medications, as well as their potential for addiction, has been a cause for concern for both patients and physicians. CASE PRESENTATIONS: Four women with long histories of migraine or frequent tension-type headache that meet the International Classification of Headache Disorders criteria for Chronic Migraine or Tension-type Headaches were given a systemic treatment(s) of autologous stromal vascular fraction or autologous ‘StroMed’ isolated from lipoaspirate. StroMed is stromal vascular fraction cells prepared by ultrasonic cavitation. Two of the four patients, both of whom are Arab women aged 40 and 36 years, ceased having migraines after 1 month, for a period of 12 to 18 months. The third patient, a Slavic woman aged 43 years, had a significant decrease in the frequency and severity of migraines with only seven migraines over 18 months. The fourth patient, an Asian woman aged 44 years, obtained a temporary decrease for a period of a month and was retreated 18 months later and has been free of migraines to date for 1 month. Pain medication was typically reduced from prescribed opioid analgesia to non-steroidal anti-inflammatory drugs and paracetamol. CONCLUSIONS: This case series is the first to provide evidence of the efficacy of autologous StroMed and stromal vascular fraction in the treatment of migraine and tension-type headache. The treatment of this disease by stromal vascular fraction adds a new dimension to its clinical applicability and suggests a relatively simple treatment that may help address the symptoms of the disease. Given what is known about the components of the stromal vascular fraction and how they act, the information presented in this case series may also further our knowledge of the etiology and pathophysiology of migraine and tension-type headaches. This treatment is simple, looks to be extremely effective and has been life changing for these patients. BioMed Central 2014-06-30 /pmc/articles/PMC4088303/ /pubmed/24981130 http://dx.doi.org/10.1186/1752-1947-8-237 Text en Copyright © 2014 Bright et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Bright, Ralph
Bright, Matthew
Bright, Pelin
Hayne, Shannon
Thomas, Wayne D
Migraine and tension-type headache treated with stromal vascular fraction: a case series
title Migraine and tension-type headache treated with stromal vascular fraction: a case series
title_full Migraine and tension-type headache treated with stromal vascular fraction: a case series
title_fullStr Migraine and tension-type headache treated with stromal vascular fraction: a case series
title_full_unstemmed Migraine and tension-type headache treated with stromal vascular fraction: a case series
title_short Migraine and tension-type headache treated with stromal vascular fraction: a case series
title_sort migraine and tension-type headache treated with stromal vascular fraction: a case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088303/
https://www.ncbi.nlm.nih.gov/pubmed/24981130
http://dx.doi.org/10.1186/1752-1947-8-237
work_keys_str_mv AT brightralph migraineandtensiontypeheadachetreatedwithstromalvascularfractionacaseseries
AT brightmatthew migraineandtensiontypeheadachetreatedwithstromalvascularfractionacaseseries
AT brightpelin migraineandtensiontypeheadachetreatedwithstromalvascularfractionacaseseries
AT hayneshannon migraineandtensiontypeheadachetreatedwithstromalvascularfractionacaseseries
AT thomaswayned migraineandtensiontypeheadachetreatedwithstromalvascularfractionacaseseries